Navigation Links
Many solid tumors carry genetic changes targeted by existing compounds
Date:5/31/2013

CHICAGO, IL (May 28, 2013)Nearly two-thirds of solid tumors carry at least one mutation that may be targeted, or medicated, by an existing compound, according to new findings from researchers Fox Chase Cancer Center that will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology on June 3. The results suggest that it may one day become commonplace for doctors to sequence tumors before deciding on a treatment regimen.

"Extended sequencing of a patient's tumor is not something that's routinely done now," says study author Patrick Boland, MD, a hematology/oncology fellow at Fox Chase. "Our ultimate hope is that, if we determine testing is worthwhile, it becomes routine for a doctor to send off a tumor sample to look for mutations before deciding on a course of treatment."

In some forms of cancer, such as lung cancer, doctors do check for a limited number of mutations. Mutations found with this focused testing only affect the treatment of a small proportion of patients. However, most tumors likely have many mutations, some of which may be targeted specifically by drugs already on the market, or under development.

To investigate, 77 patients with solid tumorsprimarily inflammatory breast cancer and colon cancer underwent genetic profiling looking for nearly 200 mutations associated with cancer. Boland and his co-author Alan Skarbnik reviewed the DNA sequencing to analyze the net results of testing and consider the potential impact on patient care.

Most of the patients96%carried one mutation or more. Nearly two-thirds had at least one mutation the researchers termed "actionable," meaning it is targeted by a drug that is on the market or in development. Many of the mutations were amplifications, in which multiple copies of a single gene were present, which ramps up its effect on the body.

Boland stresses that even though these genetic alterations are present, in many cases it's not clear which ones if any are driving the cancers. "Even if we find a [change], we don't know if it's something that's driving the tumor to grow, or something that just happened along the way." The results from this study highlight the need for more research to understand the basic biology of tumors, he notes. "We need our colleagues in the basic sciences to continue investigating the genetic underpinnings of cancer, so we can determine which mutations are most important to target."

The sequenced data was reviewed by the patients' doctors, and in some cases, they prescribed new medications that targeted the identified mutations. Even though patients had all triedand failedtreatments in the past, some responded well to the new medicine, including one patient who has been on the treatment for at least 6 months.

A major limiting factor in sequencing all tumors, says Boland, is costthe list price of the sequencing test used in the study, from the company Foundation Medicine, is nearly $6,000. "We hope that, once sequencing tumors becomes the standard of care, it will be routinely covered by insurance."

Indeed, genetic sequencing is getting more affordable, notes Boland. Once tumor DNA can be analyzed readily, doctors learn more regarding how to use that information to guide treatment, and patients get more access to medicines that target these mutations which may be beneficial. It may become commonplace for most doctors to sequence tumors before deciding how to treat them. "The expectation is that, sometime soon, these kinds of tests will be done on a routine basis," predicts Boland. "We're not there yet."


'/>"/>
Contact: Diana Quattrone
diana.quattrone@fccc.edu
215-815-7828
Fox Chase Cancer Center
Source:Eurekalert

Related medicine news :

1. New Jersey Court Consolidates Statewide Mirena IUD Lawsuits, Rottenstein Law Group LLP Reports
2. Stryker Rejuvenate Attorneys at Kershaw, Cutter & Ratinoff Push for Cases to be Consolidated and Fought in U.S. District Court in Chicago, Illinois
3. Stryker Hip Recall Lawyers at Gilman Law LLP Look Forward to Upcoming Hearing on Stryker Rejuvenate and ABG II Hip Lawsuit Consolidation
4. Cymbet EnerChip Solid State Batteries Verified 100% Biocompatible
5. Smith & Nephew Hip Recall News: Bernstein Liebhard LLP Notes Motion to Consolidate Smith & Nephew Lawsuits Filed in Tennessee State Courts
6. Solid-state controllable light filter may protect preterm infants from disturbing light
7. Transvaginal Mesh Complications Lawsuits Update: Resource4thePeople Reports Some CasesDismissed from Consolidated Litigation
8. New Instrument for High-Precision Measurements of Soy Milk Solids and Protein Concentration
9. Consolidated Facility Advises Spring Cleaning Done Now in Davis Businesses
10. AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors
11. Researchers to develop next generation immunotherapy for children with deadly solid tumors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance ... care insurance companies have a waiver for care if the client has a cognitive ... the family pays for care, is often waived, so the benefits from their insurance ...
(Date:10/13/2017)... Texas (PRWEB) , ... October 13, 2017 , ... Yisrayl ... this week that explains one of the most popular and least understood books in ... like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have tossed ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... the demand of today’s consumer and regulatory authorities worldwide. From Children’s to Adults ... tested to meet the highest standard. , These products are also: Gluten ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the ... to develop to enable prevention of a major side effect of chemotherapy in ... in pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)... Israel and NEW YORK , Sept. 27, ... with mobile health and big data solutions, today announced that its MyDario ... Please check your local TV listings for when The Dr. Oz Show ... ... season this month. ...
(Date:9/23/2017)... Pa. , Sept. 22, 2017 Janssen ... a complete response letter from the U.S. Food and ... seeking approval of sirukumab for the treatment of moderately ... letter indicates additional clinical data are needed to further ... moderately to severely active RA. ...
(Date:9/19/2017)... Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses ... today:   ... Jim ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and business ...
Breaking Medicine Technology: